[Edaily Starin JOO MEE_HEE Reporter] The movie "Spider-Man: A Brand New Day" ("Spider-Man 4") has surpassed $900 million (approximately 1.2146 trillion won) in box office revenue at the North American box office, achieving the fastest pace in history. Poster for the movie “Spider-Man: A Brand New Day.” (Photo courtesy of Sony Pictures) According to the box office tracking site Box Office Mojo on the 5th (local time), “Spider-Man 4” had accumulated $903.63 million (approximately 1.2194 trillion won) in North American box office revenue as of the previous day. This record was set just 36 days after the film’s release. The previous record for the fastest to reach this milestone was 50 days, set by “Star Wars: The Force Awakens,” which was released in 2015. “Spider-Man 4” beat that record by 14 days, making history at the North American box office. Its box office momentum is expected to continue for the time being. With the U.S. Labor Day holiday underway, the entertainment magazine *Variety* projected that *Spider-Man 4* would generate approximately $22 million (approximately 29.69 billion won) in additional revenue over the four-day holiday weekend. The film is also continuing its record-breaking run worldwide. To date, “Spider-Man 4” has grossed a cumulative total of $2.34513 billion (approximately 3.1648 trillion won) globally. This places it third on the all-time global box office list, behind “Avatar” (2009, $2.92371 billion) and “Avengers: Endgame” (2019, $2.79944 billion). Starring Tom Holland, “Spider-Man 4” tells the story of Peter Parker (played by Tom Holland), who finds himself alone in a world where even his closest friends and his girlfriend have forgotten his existence, as he faces a new villain. The film has not only been a box office success but has also received positive reviews from audiences and critics alike. On the U.S. movie and TV review site Rotten Tomatoes, the “Popcorn Index,” which reflects audience ratings, stands at 97%, while the “Tomato Index,” which reflects critics’ ratings, stands at 89%.
This week (October 6–8), startups across various sectors—including defense, biotech, and artificial intelligence (AI) image-generation platforms—secured investments from venture capital (VC) firms and…
South Korean diagnostic stocks, including Humasis, GC Green Cross MS, and Genematrix, rallied on Tuesday as investors reacted to a suspected plague exposure incident at a Russian research institute.Th…
Yuhan(000100)Overseas clinical trials for “YH32367” (nesprotamig), a bispecific antibody anticancer drug being developed by the company as a “post-Lecraza” (generic name: lazertinib) candidate, are be…